Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 10;45(6):139.
doi: 10.1007/s00296-025-05894-4.

A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis

Dorota Suszek  1 , Magdalena Popławska  2 , Jakub Prośniak  2 , Katarzyna Siemieniec  2 , Karolina Przeniosło  2 , Weronika Wallach  2 , Monika Żybowska-Męczyńska  2 , Klaudia Ostrowicz  2 , Anna Rzewuska-Fijałkowska  2 , Bożena Targońska-Stępniak  3
Affiliations
Review

A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis

Dorota Suszek et al. Rheumatol Int. .

Abstract

Systemic lupus erythematosus (SLE) patients have a significantly increased risk of developing cardiovascular disease (CVD). Despite the implementation of preventive measures and treatment of lipid disorders, as well as reduced use of glucocorticoids, CVD remains one of the leading causes of death in this patient group. It is crucial to develop an appropriate CVD risk assessment strategy that considers the distinctive characteristics of this patient population. This paper provides a comprehensive analysis of the methods used to assess CVD risk in SLE patients. It also presents effective strategies for the reduction of the effects of traditional and non-traditional risk factors for atherosclerosis.

Keywords: Atherosclerosis; Cardiovascular diseases; Cardiovascular risk; Systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Declarations. Disclaimer: No part of this review has been copied or published elsewhere in whole or in part. Conflict of interest: Authors: Dorota Suszek, Magdalena Popławska, Jakub Prośniak, Katarzyna Siemieniec, Karolina Przeniosło, Weronika Wallach, Monika Żybowska-Męczyńska, Klaudia Ostrowicz, Anna Rzewuska-Fijałkowska, Bożena Targońska - Stępniak declare that they have no conflict of interest.

References

    1. Jha SB, Rivera AP, Flores Monar GV et al (2022) Systemic lupus erythematosus and cardiovascular disease. Cureus 14(2):e22027. 10.7759/cureus.22027 - PMC - PubMed
    1. Papazoglou N, Kravvariti E, Konstantonis G et al (2024) The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford) 63(1):50–57. 10.1093/rheumatology/kead184 - PMC - PubMed
    1. Aviña-Zubieta JA, To F, Vostretsova K et al (2017) Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: A general Population-Based study. Arthritis Care Res (Hoboken) 69(6):849–856. 10.1002/acr.23018 - PubMed
    1. Urowitz MB, Bookman AA, Koehler BE et al (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60(2):221–225. 10.1016/0002-9343(76)90431-9 - PubMed
    1. Alammari Y, Albednah FA, Alharbi KA et al (2024) Cardiovascular morbidity in systemic lupus erythematosus: A Single-Center retrospective study. Cureus 16(4):e57842. 10.7759/cureus.57842 - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources